Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
TL;DR: In this article , the authors provided insight on imeglimin's action on pancreatic β-cells and the mechanisms underlying its clinical benefits, showing that Imeglimin may enhance glucose-induced insulin secretion (GIIS) and inhibit apoptosis of pancreatic cells leading to preserved β-cell mass by maintaining or restoring the functional and structural integrity of the mitochondria and the endoplasmic reticulum homeostasis.
read more
Abstract: Recent preclinical studies have provided insight on imeglimin's action on pancreatic β‐cells and the mechanisms underlying its clinical benefits. Imeglimin may enhance glucose‐induced insulin secretion (GIIS) and inhibit apoptosis of pancreatic ß‐cells leading to preserved β‐cell mass by maintaining or restoring the functional and structural integrity of the mitochondria and the endoplasmic reticulum homeostasis in pancreatic β‐cells.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
TL;DR: Imeglimin this paper is a novel oral hypoglycemic agent with a unique mechanism of action that targets mitochondrial bioenergetics, which improves function of mitochondria and the endoplasmic reticulum, which are important in the synthesis, folding, modification and transport of proteins.
Effects of imeglimin on mitochondrial functions and ischemic brain damage in young and aging rats
Evelina Paskeviciene,Kristina Skemiene,Katryna Pampuscenko,Silvija Jankeviciute,Vilmante Borutaite +4 more
Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes
Åke Sjöholm
TL;DR: This review discusses glucokinase activators (e.g., dorzagliatin) and imeglimin, novel antidiabetic agents approved for type 2 diabetes, which target insulin secretion, hepatic glucose production, and mitochondrial dysfunction, with potential disease-modifying effects and improved treatment options.
Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan
Hisayuki Katsuyama,Mariko Hakoshima,Takahiro Heshiki,Sakura Iida,Hisashi Adachi,Hidekatsu Yanai +5 more
TL;DR: Imeglimin's effectiveness in improving glycemic control and metabolic factors in T2DM patients in a real-world setting in Japan.
References
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Sophie Hallakou-Bozec,Guillaume Vial,Guillaume Vial,Micheline Kergoat,Pascale Fouqueray,Sébastien Bolze,Anne-Laure Borel,Anne-Laure Borel,Anne-Laure Borel,Eric Fontaine,Eric Fontaine,David E. Moller +11 more
TL;DR: Overall, Imeglimin appears to target a key root cause of T2D: defective cellular energy metabolism.
116
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.
TL;DR: In this paper, the authors show that Imeglimin acutely and directly amplifies insulin secretion in pancreatic islets isolated from rodents with Type 2 diabetes via a mode of action that is distinct from other known therapeutic approaches.
Imeglimin Amplifies Glucose-Stimulated Insulin Release from Diabetic Islets via a Distinct Mechanism of Action
TL;DR: Results suggest that NAD+ conversion to a second messenger, cyclic ADP ribose (cADPR) is required for Imeglimin’s effects in islets, thus representing a potential link between increased NAD+ and enhanced glucose-induced Ca2+ mobilization which is known to drive insulin granule exocytosis.
Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
Junpei Sanada,Atsushi Obata,Yoshiro Fushimi,Tomohiko Kimura,Masatoshi Shimoda,Tomoko Ikeda,Yuka Nogami,Yoshiyuki Obata,Y. Yamasaki,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto +12 more
TL;DR: Imeglimin is a new anti-diabetic drug commercialized in Japan (Twymeeg®) and has been drawing much attention in diabetes research area as well as in clinical practice as discussed by the authors .
30
A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway
Shunsuke Funazaki,Masashi Yoshida,Hodaka Yamada,Masafumi Kakei,Masanobu Kawakami,Shuichi Nagashima,Kazuo Hara,Katsuya Dezaki,Katsuya Dezaki +8 more
TL;DR: In this paper, the authors examined whether Imeglimin potentiates glucose-stimulated insulin secretion (GSIS) via the TRPM2 channel in β-cells, and they found that imeglimin increased NSCC current in β cells, and abolished this current in TRPM 2-knockout (KO) mice.
22